A61K 2239/00
Indexing codes associated with cellular immunotherapy of group a61k40/00
Official title: Indexing codes associated with cellular immunotherapy of group A61K40/00
A61K2239/00 (Indexing codes associated with cellular immunotherapy of group a61k40/00) appears on 3,505 US grants and 8,408 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,505
- Published applications
- 8,408
- Assignees
- 2,263
- Inventors
- 11,854
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 6 | 0 |
| 1995 | 5 | 0 |
| 1996 | 4 | 0 |
| 1997 | 11 | 0 |
| 1998 | 26 | 0 |
| 1999 | 13 | 0 |
| 2000 | 18 | 0 |
| 2001 | 16 | 13 |
| 2002 | 38 | 89 |
| 2003 | 19 | 91 |
| 2004 | 20 | 91 |
| 2005 | 15 | 81 |
| 2006 | 30 | 98 |
| 2007 | 15 | 59 |
| 2008 | 31 | 93 |
| 2009 | 34 | 93 |
| 2010 | 66 | 131 |
| 2011 | 54 | 130 |
| 2012 | 53 | 117 |
| 2013 | 85 | 135 |
| 2014 | 79 | 171 |
| 2015 | 90 | 187 |
| 2016 | 115 | 206 |
| 2017 | 111 | 271 |
| 2018 | 148 | 373 |
| 2019 | 149 | 503 |
| 2020 | 254 | 641 |
| 2021 | 242 | 775 |
| 2022 | 291 | 862 |
| 2023 | 320 | 835 |
| 2024 | 361 | 966 |
| 2025 | 430 | 807 |
| 2026 | 342 | 590 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 2239/46Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by theIndexing code2,256
- A61K 2239/38Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by theIndexing code2,183
- A61K 2239/31Characterized by the route of administrationIndexing code2,060
- A61K 2239/10Characterized by the structure of the chimeric antigen receptor [car]Indexing code282
- A61K 2239/27Characterized by targeting or presenting multiple antigensIndexing code223
- A61K 2239/39Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by aIndexing code10
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014